JP2006056881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006056881A5 JP2006056881A5 JP2005210382A JP2005210382A JP2006056881A5 JP 2006056881 A5 JP2006056881 A5 JP 2006056881A5 JP 2005210382 A JP2005210382 A JP 2005210382A JP 2005210382 A JP2005210382 A JP 2005210382A JP 2006056881 A5 JP2006056881 A5 JP 2006056881A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- optionally substituted
- compound according
- methylene group
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000001555 benzenes Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000016253 exhaustion Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000010030 glucose lowering effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000000521 hyperimmunizing effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005210382A JP2006056881A (ja) | 2004-07-21 | 2005-07-20 | 縮合環化合物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004213523 | 2004-07-21 | ||
| JP2005210382A JP2006056881A (ja) | 2004-07-21 | 2005-07-20 | 縮合環化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006056881A JP2006056881A (ja) | 2006-03-02 |
| JP2006056881A5 true JP2006056881A5 (https=) | 2008-08-07 |
Family
ID=36104647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005210382A Pending JP2006056881A (ja) | 2004-07-21 | 2005-07-20 | 縮合環化合物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006056881A (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080086917A (ko) * | 2005-12-29 | 2008-09-26 | 노파르티스 아게 | 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체 |
| EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
| AU2007276405A1 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| AU2007325315A1 (en) * | 2006-11-28 | 2008-06-05 | Kalypsys Inc | Heterocyclic modulators of TGR5 |
| WO2008067219A2 (en) * | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| US20080221161A1 (en) * | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| WO2009063991A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | ピリドオキサゼピン誘導体およびその用途 |
| EP2322222A4 (en) | 2008-08-07 | 2011-12-21 | Takeda Pharmaceutical | THERAPEUTIC FOR IRRITATION SYNDROME |
| WO2010016846A1 (en) * | 2008-08-08 | 2010-02-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| KR20110120866A (ko) | 2009-01-12 | 2011-11-04 | 바이오키어 인코포레이티드 | 당뇨병 치료 조성물 및 치료방법 |
| WO2012151252A2 (en) | 2011-05-02 | 2012-11-08 | Biokier, Inc. | Composition and method for treatment of diabetes |
| EA021079B1 (ru) | 2009-06-15 | 2015-03-31 | Такеда Фармасьютикал Компани Лимитед | Производные пиразинооксазепина |
| EP2463290B1 (en) | 2009-08-04 | 2014-03-05 | Takeda Pharmaceutical Company Limited | Thienooxazepine derivative |
| US9301938B2 (en) | 2009-09-23 | 2016-04-05 | Biokier, Inc. | Composition and method for treatment of diabetes |
| EP2368886A1 (en) | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| US20150073057A1 (en) | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
| CN103739615B (zh) * | 2013-12-20 | 2015-10-28 | 陕西理工学院 | 一种具有抗肿瘤活性的酮类化合物及其应用 |
| JP6660668B2 (ja) * | 2014-06-24 | 2020-03-11 | 花王株式会社 | Ｕｃｐ−１発現促進剤 |
| WO2015199097A1 (ja) * | 2014-06-24 | 2015-12-30 | 花王株式会社 | Ｕｃｐ－１発現促進剤 |
| US10758519B2 (en) | 2014-06-24 | 2020-09-01 | Kao Corporation | UCP-1 expression promoter |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) * | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5137890A (en) * | 1990-02-14 | 1992-08-11 | Ortho Pharmaceutical Corporation | 4-phenyl tetrahydropyrido(4,3-d)pyrimidines |
| JP2976097B2 (ja) * | 1995-03-24 | 1999-11-10 | 武田薬品工業株式会社 | 環状化合物、その製造法および剤 |
| JP2000038386A (ja) * | 1997-06-30 | 2000-02-08 | Nippon Kayaku Co Ltd | 新規ナフチリジン誘導体またはその塩 |
| JP2004521892A (ja) * | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
| JPWO2003104230A1 (ja) * | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
| JP2004346059A (ja) * | 2003-01-28 | 2004-12-09 | Takeda Chem Ind Ltd | 受容体作動薬 |
-
2005
- 2005-07-20 JP JP2005210382A patent/JP2006056881A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006056881A5 (https=) | ||
| US8399485B2 (en) | Acyl bipiperidinyl compounds useful as GPR 119 agonists | |
| Cotman et al. | Discovery and hit-to-lead optimization of benzothiazole scaffold-based DNA gyrase inhibitors with potent activity against Acinetobacter baumannii and Pseudomonas aeruginosa | |
| US10195186B2 (en) | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | |
| US7074816B2 (en) | 1 2 4-triazole compound | |
| Hasegawa et al. | Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists | |
| JP2009533410A5 (https=) | ||
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2009527501A5 (https=) | ||
| JP2007500715A5 (https=) | ||
| KR20080109784A (ko) | 신규 화합물 | |
| CN1534023A (zh) | 作为多巴胺－d3配位体的杂环化合物 | |
| JP2021535164A5 (https=) | ||
| JP2009524691A5 (https=) | ||
| JP2018510866A (ja) | 腸受容体を活性化させるための、ファルネソイドｘ受容体アゴニストでの、成体の潜在性自己免疫性糖尿病の治療 | |
| JP2011503081A5 (https=) | ||
| US20120130070A1 (en) | Compounds having npy y5 receptor antagonistic activity | |
| JP4527665B2 (ja) | グルカゴン類似ペプチド−１受容体アゴニスト及びその製造方法と用途 | |
| WO2004000813A1 (ja) | フェノキシピリジン誘導体又はその塩 | |
| JP2009057282A (ja) | カルボン酸誘導体又はその塩 | |
| CN104995188B (zh) | 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途 | |
| JP5931744B2 (ja) | アセチレン誘導体及びその医薬用途 | |
| WO2013063385A1 (en) | Compounds for inflammation and immune-related uses | |
| WO2012064808A1 (en) | Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses | |
| WO2011077711A1 (ja) | 新規な２－ピリドン誘導体及びこれを含有する医薬 |